Company profile · Warsaw, Poland

Molecure

Small-Molecule Drug Discovery · Clinical-stage drug discovery

Molecure is mapped as a Polish small-molecule discovery anchor with cluster relevance across German platform and translational nodes.

Lead
Marcin Jan Szumowski (verified ↗)
Address
Zwirki i Wigury 101, 02-089 Warsaw, Poland (source ↗)
Compliance
Not yet on record
Last reviewed
14 Mar 2026 (3mo ago)
Scale
Clinical-stage drug discovery
Capabilities
Medicinal Chemistry · Fibrosis and Inflammation Programs · Oncology Target Discovery
Founded
2012
Headcount
51-200
LinkedIn
Company page (open ↗)
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Marcin Jan Szumowski

President of the Board and Chief Executive Officer

Check official leadership source
Full addressZwirki i Wigury 101, 02-089 Warsaw, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official Molecure contact page listing the headquarters and laboratories at Zwirki i Wigury 101 in Warsaw.

Open source
Operating profile

Clinical-stage drug discovery

Warsaw, Poland. Small-Molecule Drug Discovery. Review completed on 14 Mar 2026.

2026 technical specializationSmall-Molecule Drug Discovery
Core capabilities
Medicinal ChemistryFibrosis and Inflammation ProgramsOncology Target Discovery
Governance

Polish and EU medicinal product oversight

Clinical-stage biotech platform

Editorial note

Small-Molecule Drug Discovery

Molecure is mapped as a Polish small-molecule discovery anchor with cluster relevance across German platform and translational nodes.

Related companies
Editorial note

Molecure is mapped as a Polish small-molecule discovery anchor with cluster relevance across German platform and translational nodes.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 14 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Medicinal Chemistry
Fibrosis and Inflammation Programs
Oncology Target Discovery
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceMolecure 2 April 2025 investor meeting announcement naming Dr Marcin Szumowski as Chief Executive Officer and President of the Management Board.Source origin: molecure.comOpen source
Supporting evidenceMolecure About page and management section.Source origin: molecure.comOpen source
Physical-site evidenceOfficial Molecure contact page listing the headquarters and laboratories at Zwirki i Wigury 101 in Warsaw.Source origin: molecure.comOpen source
Infrastructure

Declared infrastructure

Medicinal chemistry labs
Discovery biology platforms
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Molecure located?
Molecure operates from Zwirki i Wigury 101, 02-089 Warsaw, Poland, Warsaw, Poland.
Who runs Molecure?
Molecure is led by Marcin Jan Szumowski, President of the Board and Chief Executive Officer. Verified 14 Mar 2026.
What does Molecure do?
Molecure is mapped as a Polish small-molecule discovery anchor with cluster relevance across German platform and translational nodes. Core capabilities: Medicinal Chemistry, Fibrosis and Inflammation Programs, Oncology Target Discovery.
Editorial context

Related technical briefs

Briefs that name Warsaw as a covered market or city.